Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Manabu Hayashi, Kazumichi Abe, Tatsuro Sugaya, Yosuke Takahata, Masashi Fujita, Atsushi Takahashi, Hiromasa Ohira
AIM: Myostatin is a myokine involved in muscle mass regulation. The associations between circulating myostatin levels and clinical characteristics in patients with acute liver failure (ALF) and late-onset hepatic failure (LOHF) are unclear. METHODS: In this retrospective study, 51 patients with ALF or LOHF were included. Serum myostatin was measured using an enzyme-linked immunosorbent assay. RESULTS: Myostatin levels were significantly lower in patients with ALF and LOHF than in controls (ALF/LOHF: 2522 pg/mL, controls: 3853 pg/mL, p = 0...
April 24, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
#2
JOURNAL ARTICLE
Naga Chalasani, Eduardo Vilar-Gomez, Rohit Loomba, Katherine P Yates, Anna Mae Diehl, Brent A Neuschwander-Tetri, Srinivasan Dasarathy, Kris V Kowdley, Norah Terrault, Laura A Wilson, James Tonascia, Arun Sanyal
BACKGROUND AND AIMS: The patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 variant is associated with Steatotic Liver Disease (SLD) and its progression. We examined the association between PNPLA3 and the development of major adverse liver outcomes (MALO) and how non-modifiable and modifiable conditions modify this relationship. APPROACH AND RESULTS: 2,075 adults with biopsy-confirmed Metabolic-Associated SLD (MASLD) were enrolled in the MASLD CRN studies and followed prospectively until death, transplant, or withdrawal of consent...
April 23, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#3
JOURNAL ARTICLE
Alan L Hutchison, K Gautham Reddy, Sonali Paul, Anjana A Pillai
No abstract text is available yet for this article.
April 23, 2024: Liver Transplantation
#4
JOURNAL ARTICLE
Fredrik Åberg, Z Gordon Jiang, Helena Cortez-Pinto, Ville Männistö
Alcohol-associated liver disease (ALD), as highlighted in this narrative review, is a major public health concern, increasingly impacting global disease burden and premature mortality. In 2019, ALD accounted for the loss of 11 million life-years worldwide. The rising number of deaths and disability-adjusted life years attributed to ALD, particularly pronounced in America, are alarming. Projections suggest that the economic impact of ALD, as seen in the United States, could potentially double by 2040. ALD is increasingly prevalent among younger adults and has become the leading cause for liver transplantation in both America and Europe...
April 19, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#5
Jiajun Li, Sile Wan, Fukai Wen, Qingyu Li, Yifeng Cui, Zhaoyang Lu, Han Lin
Hepatic myelopathy (HM) is a rare neurological complication in the end stage of many liver diseases and is characterized by bilateral spastic paraparesis without sensory and sphincter dysfunction. It occurs owing to metabolic disorders and central nervous system dysfunction associated with cirrhosis. Without timely and effective clinical intervention, the prognosis of these patients is devastating. Although liver transplantation (LT) is an effective treatment for HM, the prognosis of these patients remains unsatisfactory...
April 28, 2024: Journal of Clinical and Translational Hepatology
#6
JOURNAL ARTICLE
Yongsheng Tang, Zenan Yuan, Xu Lu, Yingqiu Song, Shuguang Zhu, Chunhui Qiu, Qi Zhang, Binsheng Fu, Changchang Jia, Hua Li
BACKGROUND AND AIMS: Hepatic ischemia-reperfusion injury (HIRI) is a prevalent complication of liver transplantation, partial hepatectomy, and severe infection, necessitating the development of more effective clinical strategies. Receptor activity-modifying protein 1 (RAMP1), a member of the G protein-coupled receptor adapter family, has been implicated in numerous physiological and pathological processes. The study aimed to investigate the pathogenesis of RAMP1 in HIRI. METHODS: We established a 70% liver ischemia-reperfusion model in RAMP1 knockout (KO) and wild-type mice...
April 28, 2024: Journal of Clinical and Translational Hepatology
#7
JOURNAL ARTICLE
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi-Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Wan-Long, Ming-Jong Bair, Ming-Lung Yu
BACKGROUNDS AND AIM: Chronic hepatitis C (CHC) patients who fail antiviral therapy have a high risk of developing hepatocellular carcinoma (HCC). We investigated the effects of metformin and statins, commonly used to treat diabetes mellitus (DM) and hyperlipidemia (HLP), on HCC risk in CHC patients who failed antiviral therapy. METHODS: CHC patients with failed interferon-based therapy were enrolled in a large-scale multicenter cohort study in Taiwan (T-COACH). HCC occurrence 1...
April 19, 2024: Clinical and Molecular Hepatology
#8
JOURNAL ARTICLE
L L Cao, J G Yan, D N Feng, Y Dong, Z Q Xu, F C Wang, Y J Gao, S S Zhu, M Zhang
Objective: To analyze the clinical manifestations, pathology, and gene variant characteristics in children with progressive familial intrahepatic cholestasis type 3 (PFIC3). Methods: This retrospective study assessed the clinical manifestations, pathological features, gene variants, and prognosis data of 11 children with PFIC3 hospitalized in the Department of Hepatology, Fifth Medical Center, PLA General Hospital, from January 2015 to December 2022. Panel or whole exome sequencing was performed on the probands, followed by Sanger sequencing for verification within the family...
April 16, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
#9
JOURNAL ARTICLE
Rheun-Chuan Lee, Po-Chin Liang, Huei-Lung Liang, Yung-Fang Chen, Chun-Yen Yu, Pin-Nan Cheng, Chien-Fu Hung, Cheng-Yuan Hsia, Hsueh-Chou Lai, Ming-Chih Ho, Yu-Fan Cheng, Yi-Sheng Liu, Yee Chao, Chien-Hung Chen
BACKGROUND AND AIM: The REgistry of Selective Internal radiation therapy in AsiaNs (RESIN) was a multicenter, single-arm, prospective, observational study of 90 Y resin microspheres in patients with hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) from Taiwan. RESIN is the first real-life clinical study of this therapy in an Asian cohort. Study objectives were to evaluate the safety and efficacy of 90 Y resin microspheres. METHODS: Adults with HCC or mCRC scheduled to receive SIRT with 90 Y resin microspheres were included...
April 13, 2024: Journal of Gastroenterology and Hepatology
#10
JOURNAL ARTICLE
Winston Dunn, Yanming Li, Ashwani K Singal, Douglas A Simonetto, Luis A Díaz, Francisco Idalsoaga, Gustavo Ayares, Jorge Arnold, María Ayala-Valverde, Diego Perez, Jaime Gomez, Rodrigo Escarate, Eduardo Fuentes-López, Carolina Ramirez-Cadiz, Dalia Morales-Arraez, Wei Zhang, Steve Qian, Joseph C Ahn, Seth Buryska, Heer Mehta, Nicholas Dunn, Muhammad Waleed, Horia Stefanescu, Andreea Bumbu, Adelina Horhat, Bashar Attar, Rohit Agrawal, Joaquín Cabezas, Victor Echavaría, Berta Cuyàs, Maria Poca, German Soriano, Shiv K Sarin, Rakhi Maiwall, Prasun K Jalal, Fátima Higuera-de-la-Tijera, Anand V Kulkarni, P Nagaraja Rao, Patricia Guerra-Salazar, Lubomir Skladaný, Natália Kubánek, Veronica Prado, Ana Clemente-Sanchez, Diego Rincon, Tehseen Haider, Kristina R Chacko, Gustavo A Romero, Florencia D Pollarsky, Juan C Restrepo, Luis G Toro, Pamela Yaquich, Manuel Mendizabal, Maria L Garrido, Sebastián Marciano, Melisa Dirchwolf, Victor Vargas, César Jiménez, David Hudson, Guadalupe García-Tsao, Guillermo Ortiz, Juan G Abraldes, Patrick S Kamath, Marco Arrese, Vijay H Shah, Ramon Bataller, Juan P Arab
BACKGROUND AIMS: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence (AI) in a global cohort, we sought to derive and validate an enhanced prognostic model. APPROACH AND RESULTS: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled AH patients per NIAAA criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients)...
April 12, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#11
REVIEW
Lukas Bethlehem, Maria Manuela Estevinho, Ari Grinspan, Fernando Magro, Jeremiah J Faith, Jean-Frederic Colombel
Microbiota therapeutics that transplant faecal material from healthy donors to people with mild-to-moderate ulcerative colitis have shown the potential to induce remission in about 30% of participants in small, phase 2 clinical trials. Despite this substantial achievement, the field needs to leverage the insights gained from these trials and progress towards phase 3 clinical trials and drug approval, while identifying the distinct clinical niche for this new therapeutic modality within inflammatory bowel disease (IBD) therapeutics...
May 2024: Lancet. Gastroenterology & Hepatology
#12
REVIEW
Serena Porcari, William Fusco, Igor Spivak, Marcello Fiorani, Antonio Gasbarrini, Eran Elinav, Giovanni Cammarota, Gianluca Ianiro
The gut microbiome is acknowledged as a key determinant of human health, and technological progress in the past two decades has enabled the deciphering of its composition and functions and its role in human disorders. Therefore, manipulation of the gut microbiome has emerged as a promising therapeutic option for communicable and non-communicable disorders. Full exploitation of current therapeutic microbiome modulators (including probiotics, prebiotics, and faecal microbiota transplantation) is hindered by several factors, including poor precision, regulatory and safety issues, and the impossibility of providing reproducible and targeted treatments...
May 2024: Lancet. Gastroenterology & Hepatology
#13
JOURNAL ARTICLE
Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-Ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin
BACKGROUND/AIMS: Quick sequential organ failure assessment (qSOFA) has been suggested to identify those who have poor outcomes in patients with suspected infection. We aimed to evaluate the ability of the modified qSOFA (m-qSOFA) to identify high-risk patients in acutely deteriorated patients with chronic liver disease (CLD), especially acute-on-chronic liver failure (ACLF). METHODS: We used the data of both Korean Acute-on-Chronic Liver Failure (KACLiF) and Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) cohorts...
April 11, 2024: Clinical and Molecular Hepatology
#14
JOURNAL ARTICLE
Shuai Wang, Xiaohong Lin, Yunhua Tang, Yichen Liang, Min Zhang, Zhonghao Xie, Yiwen Guo, Yuqi Dong, Qiang Zhao, Zhiyong Guo, Dongping Wang, Xiaoshun He, Weiqiang Ju, Maogen Chen
BACKGROUND & AIMS: The shortage of donor livers hinders the development of liver transplantations. This study aimed to clarify the poor outcomes of functioned marginal liver grafts (FMLs) and provide evidence for the improvement of ischemia-free liver transplantation (IFLT) on transplantation with FMLs. METHODS: Propensity score matching was used to control for confounding factors. The outcomes of the control group and FMLs were compared to demonstrate the negative impact of FMLs in liver transplantation patients...
April 11, 2024: Clinical and Molecular Hepatology
#15
REVIEW
Osvely Mendez-Guerrero, Anaisa Carranza-Carrasco, Luis Alberto Chi-Cervera, Aldo Torre, Nalu Navarro-Alvarez
Cirrhosis is considered a growing cause of morbidity and mortality, which represents a significant public health problem. Currently, there is no effective treatment to reverse cirrhosis. Treatment primarily centers on addressing the underlying liver condition, monitoring, and managing portal hypertension-related complications, and evaluating the potential for liver transplantation in cases of decompensated cirrhosis, marked by rapid progression and the emergence of complications like variceal bleeding, hepatic encephalopathy, ascites, malnutrition, and more...
March 14, 2024: World Journal of Gastroenterology: WJG
#16
EDITORIAL
Melissa G Kaltenbach, Jessica P E Davis, Atoosa Rabiee
No abstract text is available yet for this article.
2024: Journal of Clinical and Experimental Hepatology
#17
JOURNAL ARTICLE
Hélène Donnadieu, Georges-Philippe Pageaux
No abstract text is available yet for this article.
April 2024: JHEP reports: innovation in hepatology
#18
Culture-Negative Neutrocytic Ascites in a Patient With Cardiac Ascites From End-Stage Heart Failure.
Kori X Ormachea, Lennon Gregor, Janina Quintero, Bistees George, Sandeep Singh
There are two significant groups of infection regarding ascitic fluid: spontaneous bacterial peritonitis (SBP) and culture-negative neutrocytic ascites (CNNA). SBP and CNNA typically occur in patients with cirrhosis. A 46-year-old male with end-stage biventricular heart failure presented with a heart failure exacerbation. He was treated with intravenous diuretics with the improvement of hypervolemia. He remained hospitalized to undergo an evaluation for tricuspid valve repair, but given the severity of his bi-ventricular heart failure, he underwent a heart transplant evaluation...
March 2024: Curēus
#19
JOURNAL ARTICLE
R Sun, T Li, W H Ren
Hepatic sinusoidal obstruction syndrome (HSOS) is a type of secondary vascular disease of the liver that is mainly associated with the ingestion of pyrrole alkaloids (PAs) and hematopoietic stem cell transplantation (HSCT) treatment, resulting in severe liver dysfunction, multiple organ failure, and even death. Hepatic sinusoidal dilatation and obstruction, hepatocyte coagulative necrosis, and hepatic lobular inflammation are the main pathological manifestations of HSOS. The key initiating process for the pathogenesis of HSOS is damage to liver sinusoidal endothelial cells (LSECs)...
March 20, 2024: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
#20
REVIEW
Surender Singh Sehrawat, Madhumita Premkumar
The management of acute liver failure (ALF) in modern hepatology intensive care units (ICU) has improved patient outcomes. Critical care management of hepatic encephalopathy, cerebral edema, fluid and electrolytes; prevention of infections and organ support are central to improved outcomes of ALF. In particular, the pathogenesis of encephalopathy is multifactorial, with ammonia, elevated intra-cranial pressure and systemic inflammation playing a central role. Although ALF remains associated with high mortality, the availability of supportive care, including organ failure support such as plasma exchange, timely mechanical ventilation or continuous renal replacement therapy, either conservatively manages patients with ALF or offers bridging therapy until liver transplantation...
April 5, 2024: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
